NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

I’m hoping that we’ll soon hear more about collaborations between Moffitt and Roswell Park and their shared research on dendritic cell technology and the combo research involving other agents like pembrolizumab and Ampligen.

Congratulations to the Moffitt research team for their outstanding work that’s recently been in the news and published in JAMA Oncology! Moffitt is the only NCI-designated cancer center in the state of Florida!

Notably, Northwest Bio’s recent 10-K referenced ongoing negotiations to potentially acquire a company with dendritic cell-related technology. Given the long-standing collaboration between Roswell Park and Moffitt in DC research and development, an acquisition of ImmunoRestoration by NWBO would seem logical and quite possible!

Dr. Brian Czerniecki of Moffitt is the Chief Medical & Scientific Advisor at ImmunoRestoration (a privately owned dendritic cell company).

Showers of Hope 2025

Showers of Hope 2024

https://ecancer.org/en/news/25765-innovative-immunotherapy-shows-promise-in-early-clinical-trial-for-breast-cancer

sec.gov NWBO 10-K, p.26 Commercial Collaborations




https://www.immunorestoration.com/welcome

Just a week after giving birth, Dallas Carroll was diagnosed with stage 4 breast cancer. Now, an experimental dendritic cell vaccine is giving her a shot at a cure—proof that innovative treatments are saving lives.

Read her full story: https://t.co/Hwq0iigidQ#MoffittImpact pic.twitter.com/tKUQWyVUcm

— Moffitt Cancer Center (@MoffittNews) March 5, 2025

Intratumoral delivery of dendritic cells combined with anti-HER2 antibodies is safe and effective in altering the tumor microenvironment and inducing dramatic tumor regression prior to chemotherapy in early-stage HER2-positive breast cancer. https://t.co/POtzlxarw5 pic.twitter.com/KDtUqwu6Jw

— JAMA Oncology (@JAMAOnc) February 25, 2025

https://clinicaltrials.gov/study/NCT05325632

https://www.abcactionnews.com/news/anchors-report/young-florida-mom-receives-experimental-vaccine-hope-at-moffitt-cancer-center


https://www.roswellpark.org/newsroom/201909-roswell-park-moving-unique-immunotherapy-platform-forward-642-million-dod-grant





https://www.moffitt.org/for-healthcare-professionals/clinical-perspectives/clinical-perspectives-story-archive/innovative-dendritic-cell-vaccine-trial-provides-hope-for-breast-cancer-patients-with-leptomeningeal-disease/

https://clinicaltrials.gov/study/NCT05809752?term=NCT05809752&rank=1

https://www.moffitt.org/endeavor/archive/using-first-of-its-kind-vaccine-to-treat-leptomeningeal-disease/

https://www.moffitt.org/taking-care-of-your-health/taking-care-of-your-health-story-archive/a-mothers-fight-heathers-journey-with-leptomeningeal-disease/


https://meetings.asco.org/abstracts-presentations/238290



https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS2090

https://academic.oup.com/noa/article/6/Supplement_1/i5/7726438

LP has had some past associations with Moffitt or its subsidiaries:

🎧 Ready to explore The ImmunoVerse?

This new podcast, hosted by Moffitt Cancer Center CEO, Dr. Patrick Hwu, takes you inside the ever-evolving world of immunotherapy, where science innovation is transforming how we look at and treat cancer. #TheImmunoVerse

🎤 First episode… https://t.co/2mlMnvnUeQ

— Moffitt Cancer Center (@MoffittNews) April 18, 2025

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html